share_log
  • Headlines
  • Sheung Moon Holdings (08523) received guidance on resumption of trading from the Hong Kong Stock Exchange.

常满控股(08523)接获联交所复牌指引

Sheung Moon Holdings (08523) received guidance on resumption of trading from the Hong Kong Stock Exchange.

Zhitong Finance ·  Oct 14 20:11

Sheung Moon (08523) announced that on October 9, 2024, the company received a letter from the Stock Exchange, in which...

Wisetong Financial APP News, Sheung Moon (08523) announced that on October 9, 2024, the company received a letter from the Stock Exchange detailing the resumption guidance for trading of the company's shares: publish any unpublished financial performance according to the GEM listing rules and address any audit revisions; demonstrate compliance with Rule 17.26 of the GEM listing rules; and provide the market with all significant information for shareholders and investors to assess the company's status.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Related Stocks Related Stocks
    Symbol Mini Chart Latest Price
    BOSATECH
    08140
    -- 0.109
    C CARBONNEUTRAL
    01372
    -- 0.300
    S&T HLDGS
    03928
    -- 2.860
    WING LEE DEV
    09639
    -- 0.430
    WAN KEI GROUP
    01718
    -- 0.270

    Unlock the Full List

    Latest
    19:02
    R&F PROPERTIES has been listed as a trust-breaking executor due to refusal to fulfill obligations established by effective legal documents.
    R&F PROPERTIES+1.39%
    19:02
    Guancheng New Materials: Oriental Assets increases investment in Datong New Materials by 0.3 billion yuan.
    Citychamp Dartong Advanced Materials0.00%
    19:02
    The Stoxx Europe 600 Index fell by 2%, reaching 496.52 points. Novo-Nordisk A/S's stock price plummeted by 27%, marking the largest single-day drop in 22 years. This was due to the disappointing trial results of Novo-Nordisk A/S's weight loss drug CagriSema. On Friday, Novo-Nordisk A/S announced that its experimental next-generation obesity drug Cagrisema helped overweight patients lose 22.7% of their weight in a late-stage trial, falling short of the expected 25%, leading to a significant decline in its stock price.